Update on key previously proposed candidate genes for schizophrenia

Current Opinion in Psychiatry

Volumn 22, Issue 2, 2009, Pages 147-153

  Schwab, Sibylle G ^a,b,c,e   Wildenauer, Dieter B ^a,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d GRAYLANDS HOSPITAL   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Candidate genes; Copy number repeat; Meta analysis; Schizophrenia

Indexed keywords

AMINO ACID OXIDASE; DNA; DOPAMINE RECEPTOR; DYSBINDIN; GUANINE NUCLEOTIDE BINDING PROTEIN; NEU DIFFERENTIATION FACTOR;

DNA SEQUENCE; GENE IDENTIFICATION; GENE ISOLATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CARRIER PROTEINS; DNA; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; GENETIC MARKERS; GENETIC STRUCTURES; GENETIC VARIATION; HUMANS; LINKAGE (GENETICS); MICE; NERVE TISSUE PROTEINS; NEUREGULIN-1; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, DOPAMINE; RGS PROTEINS; RISK FACTORS; SCHIZOPHRENIA; SOCIAL ENVIRONMENT;

EID: 62349085552     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328325a598     Document Type: Review

References (76)

1. Merikangas KR, Risch N. Will the genomics revolution revolutionize psychiatry? Am J Psychiatry 2003; 160:625-635.
2. Craddock N, O'Donovan MC, Owen MJ. Phenotypic and genetic complexity of psychosis. Invited commentary on ... Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiatry 2007; 190:200-203.
3. McClellan JM, Susser E, King MC. Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiatry 2007; 190:194-199.
4. Roeder K, Bacanu SA, Wasserman L, Devlin B. Using linkage genome scans to improve power of association in genome scans. Am J Hum Genet 2006; 78:243-252.
5. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 40:827-834. The authors report on a meta-analysis based on the most comprehensive compilation of schizophrenia association reports available today.
6. Shi J, Gershon ES, Liu C. Genetic associations with schizophrenia: metaanalyses of 12 candidate genes. Schizophr Res 2008; 104:96-107.
7. Mimics K, Middleton FA, Stanwood GD, et al. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 2001; 6:293-301.
8. Brzustowicz LM, Hodgkinson KA, Chow EW, et al. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science 2000; 288:678-682.
9. Berman DM, Wilkie TM, Oilman AG. GAIP and RGS4 are GTPase-activating proteins for the Gi subfamily of G protein alpha subunits. Cell 1996; 86:445-452.
10. Chowdari KV, Mimics K, Semwal P, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002; 11:1373-1380.
11. Bowden NA, Scott PJ, Tooney PA. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr Res 2007; 89:165-168.
12. Erdely HA, Tamminga CA, Roberts RC, Vogel MW. Regional alterations in RGS4 protein in schizophrenia. Synapse 2006; 59:472-479.
13. Stuart Gibbons A, Scarr E, McOmish CE, et al. Regulator of G-protein signalling 4 expression is not altered in the prefrontal cortex in schizophrenia. Aust N Z J Psychiatry 2008; 42:740-745.
14. Buckholtz JW, Meyer-Lindenberg A, Honea RA, et al. Allelic variation in RGS4 impacts functional and structural connectivity in the human brain. J Neurosci 2007; 27:1584-1593.
15. Lane HY, Liu YC, Huang CL, et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J Clin Psychopharmacol 2008; 28:64-68.
16. Blouin JL, Dombroski BA, Nath SK, et al. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 1998; 20:70-73.
17. Lin MW, Curtis D, Williams N, et al. Suggestive evidence for linkage of schizophrenia to markers on chromosome 13q14.1-q32. Psychiatr Genet 1995; 5:117-126.
18. Shaw SH, Kelly M, Smith AB, et al. A genome-wide search for schizophrenia susceptibility genes. Am J Med Genet 1998; 81:364-376.
19. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002; 99:13675-13680.
20. Martineau M, Baux G, Mothet JP. D-serine signalling in the brain: friend and foe. Trends Neurosci 2006; 29:481-491.
21. Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006; 14:660-668.
22. Wildenauer DB, Schwab SG, Maier W, Detera-Wadleigh SD. Do schizophrenia and affective disorder share susceptibility genes? Schizophr Res 1999; 39:107-111; discussion 60.
23. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71:877-892.
24. Stefansson H, Sarginson J, Kong A, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003; 72:83-87.
25. Li D, Collier DA, He L Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006; 15:1995-2002.
26. Munafo MR, Attwood AS, Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull 2008; 34:9-12.
27. Munafo MR, Thiselton DL, Clark TG, Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 2006; 11:539-546.
28. Gardner M, Gonzalez-Neira A, Lao O, et al. Extreme population differences across neuregulin 1 gene, with implications for association studies. Mol Psychiatry 2006; 11:66-75.
29. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006; 60:132-140.
30. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008; 9:437-452. This review provides an excellent summary on what is known about NRG1 in context with schizophrenia.
31. Hashimoto R, Straub RE, Weickert CS, et al. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 2004; 9:299-307.
32. Law AJ, Shannon Weickert C, Hyde TM, et al. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience 2004; 127:125-136.
33. Colantuoni C, Hyde TM, Mitkus S, et al. Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Struct Funct 2008; 213:255-271. The authors report on changes in expression levels of putative schizophrenia susceptibility genes during human ageing. The results can be regarded as highly relevant to the field of schizophrenia genetics.
34. Benzel I, Bansal A, Browning BL, et al. Interactions among genes in the ErbB-neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behav Brain Funct 2007; 3:31.
35. Nicodemus KK, Luna A, Vakkalanka R, et al. Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. Mol Psychiatry 2006; 11:1062-1065.
36. Norton N, Moskvina V, Morris DW, et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006; 1416:96-101.
37. Shiota S, Tochigi M, Shimada H, et al. Association and interaction analyses of NRG1 and ERBB4 genes with schizophrenia In a Japanese population. J Hum Genet 2008; 53:929-935.
38. Straub RE, MacLean CJ, O'Neill FA, et al. A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet 1995; 11:287-293.
39. Schwab SG, Albus M, Hallmayer J, et al. Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. Nat Genet 1995; 11:325-327.
40. Straub RE, Jiang Y, MacLean CJ, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002; 71:337-348.
41. Schwab SG, Knapp M, Mondabon S, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sibpair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003; 72:185-190.
42. Kirov G, Ivanov D, Williams NM, et al. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biol Psychiatry 2004; 55:971-975.
43. Van Den Bogaert A, Schumacher J, Schulze TG, et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am J Hum Genet 2003; 73:1438-1443,
44. Talbot K, Eidem WL, Tinsley CL, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004; 113:1353-1363.
45. Weickert CS, Straub RE, McClintock BW, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004; 61:544-555.
46. Bray NJ, Buckland PR, Owen MJ, O'Donovan MC. Cis-acting variation in the expression of a high proportion of genes in human brain. Hum Genet 2003; 113:149-153.
47. Bray NJ, Preece A, Williams NM, et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet 2005; 14:1947-1954.
48. Numakawa T, Yagasaki Y, Ishimoto T, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004; 13:2699-2708.
49. Iizuka Y, Sei Y, Weinberger DR, Straub RE. Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J Neurosci 2007; 27:12390-12395. This paper published in November 2007 provides the first evidence that dysbindin might be involved in dopaminergic signalling.
50. DeLisi LE, Shaw SH, Crow TJ, et al. A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159:803-812.
51. Faraone SV, Matise T, Svrakic D, et al. Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. Am J Med Genet 1998; 81:290-295.
52. Schwab SG, Hallmayer J, Albus M, et al. Further evidence for a susceptibility locus on chromosome 10p14-p11 in 72 families with schizophrenia by nonparametric linkage analysis. Am J Med Genet 1998; 81:302-307.
53. Schwab SG, Knapp M, Sklar P, et al. Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase llalpha gene (PIP5K2A) with schizophrenia. Mol Psychiatry 2006; 11:837-846.
54. Bakker SC, Hoogendoorn ML, Hendriks J, et al. The PIP5K2A and RGS4 genes are differentially associated with deficit and nondeficit schizophrenia. Genes Brain Behav 2007; 6:113-119.
55. Fedorenko O, Strutz-Seebohm N, Henrion U, et al. A schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M channels. Psychopharmacology (Berl) 2008; 199:47-54. The authors report on the functional implication of a schizophrenia-associated DNA sequence variation.
56. Hansen HH, Ebbesen C, Mathiesen C, et al. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat J Pharmacol Exp Ther 2006; 318:1006-1019.
57. Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004; 36:131-137.
58. Sanders AR, Duan J, Levinson DF, et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 2008; 165:497-506.
59. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004; 101:5099-5104.
60. Tan HY, Nicodemus KK, Chen Q, et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008; 118:2200-2208. This report reveals a functional link between AKT1 and brain measures influenced by dopaminergic signalling.
61. Millar JK, Christie S, Anderson S, et al. Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol Psychiatry 2001; 6:173-178.
62. Chubb JE, Bradshaw NJ, Scares DC, et al. The DISC locus in psychiatric illness. Mol Psychiatry 2008; 13:36-64. The authors summarize the complex biochemical and genetic evidence of DISC1 and its link to schizophrenia.
63. Ross CA, Margolis RL, Reading SA, et al. Neurobiology of schizophrenia. Neuron 2006; 52:139-153.
64. Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000; 9:1415-1423.
65. Schurov IL, Handford EJ, Brandon NJ, Whiting PJ. Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol Psychiatry 2004; 9:1100-1110.
66. Beckmann JS, Estivill X, Antonarakis SE. Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. Nat Rev Genet 2007; 8:639-646.
67. Kirov G, Gumus D, Chen W, et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 2008; 17:458-465.
68. Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008; 455:232-236. A systematic screen for structural DNA variation using a large number of cases and controls is reported. First reliable evidence for involvement of DNA CNVs in schizophrenia is provided.
69. The-International-Schizophrenia-Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008; 455:237-241. A systematic screen for structural DNA variation using a large number of cases and controls is reported. First reliable evidence for involvement of DNA CNVs in schizophrenia is provided.
70. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008; 320:539-543.
71. Xu B, Roos JL, Levy S, et al. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 2008; 40: 880-885.
72. Sutrala SR, Goossens D, Williams NM, et al. Gene copy number variation in schizophrenia. Schizophr Res 2007; 96:93-99.
73. Sutrala SR, Norton N, Williams NM, Buckland PR. Gene copy number variation in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2008; 1478:606-611.
74. Bassett AS, Hodgkinson K, Chow EW, et al. 22q11 deletion syndrome in adults with schizophrenia. Am J Med Genet 1998; 81:328-337.
75. Karayiorgou M, Gogos JA. The molecular genetics of the 22q11-associated schizophrenia. Brain Res Mol Brain Res 2004; 132:95-104.
76. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999; 56: 940-945.